Ishaqui Azfar Athar, Khan Amer Hayat, Syed Sulaiman Syed Azhar, Alsultan Muhammad, Khan Irfanullah
Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia / Department of Pharmacy, King Abdulaziz Hospital, Ministry of National Guard Health - Health Affairs, Alahsa, Saudi Arabia / King Abdullah International Medical Research Center, Alahsa, Saudi Arabia.
Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Pak J Pharm Sci. 2020 Jul;33(4(Supplementary)):1763-1770.
Secondary bacterial infection is considered as a major complication associated with severe Influenza-A (H1N1)pdm09 infection responsible for the mortalities and morbidities worldwide. Use of antibiotics in viral Influenza infection is still debatable. All the confirmed diagnosed hospitalized Influenza-A (H1N1)pdm09 infection patients fulfilling inclusion/exclusion criteria during the study period were divided into two groups based on drug therapy for initial 72 hours. Group-1 included those patients who received oral oseltamivir alone while Group-2 included patients who were initiated on oseltamivir in combination with empiric cephalosporin antibiotic within 6-8 hours after hospitalization. The patients of both groups were assessed for incidences of various complication associated with Influenza-A (H1N1)pdm09 infection. A total of 227 and 116 patients were enrolled for Group-1 and Group-2 respectively. The incidences of secondary bacterial infections were significantly less (P<0.05). Moreover, length of stay in hospitalization, need of ICU admission, multiple organ failure and need of respiratory support were also significantly less (P<0.05) for Group-2 patients. Majority of patients that suffered complications were unvaccinated and aged more than 50 years with multiple comorbidities. Among cephalosporins, cefuroxime was found to be least effective in prevention of Influenza associated complications. Early initiation of empiric antibiotic therapy in combination with oseltamivir can prevent complications associated with Influenza-A (H1N1)pdm09 infection especially in elderly and unvaccinated high risk patients. Different combinations of antibiotics and antiviral medications need to be analysed for the prevention of severe Influenza infection complications.
继发性细菌感染被认为是与甲型(H1N1)pdm09严重流感感染相关的主要并发症,该感染导致了全球范围内的死亡和发病。在病毒性流感感染中使用抗生素仍存在争议。在研究期间,所有确诊并住院的符合纳入/排除标准的甲型(H1N1)pdm09流感感染患者,根据最初72小时的药物治疗分为两组。第一组包括仅接受口服奥司他韦的患者,而第二组包括住院后6 - 8小时内开始使用奥司他韦联合经验性头孢菌素抗生素的患者。对两组患者评估与甲型(H1N1)pdm09流感感染相关的各种并发症的发生率。第一组和第二组分别纳入了227例和116例患者。第二组继发性细菌感染的发生率显著更低(P<0.05)。此外,第二组患者的住院时间、入住重症监护病房的需求、多器官功能衰竭和呼吸支持的需求也显著更低(P<0.05)。大多数发生并发症的患者未接种疫苗,年龄超过50岁且有多种合并症。在头孢菌素中,发现头孢呋辛在预防流感相关并发症方面效果最差。早期联合奥司他韦启动经验性抗生素治疗可预防与甲型(H1N1)pdm09流感感染相关的并发症,尤其是在老年和未接种疫苗的高危患者中。需要分析不同抗生素和抗病毒药物组合以预防严重流感感染并发症。